Neuron-D
Neuron-D
  • Main
  • About us
    • Our Team
    • Our Partners
    • Our Business Model
  • Our Science
    • History
    • Unique 3D Approach
    • Patented Technology
    • Scientific Publications
  • Our products
    • 3D Alzheimer's & TAUpathy
    • 3D Brain Development
    • 3D Toxicity
    • 3D Glioblastoma ex vivo
    • 3D Customizable Products
  • Our facilities
  • Proprietary Rights
  • News
  • More
    • Main
    • About us
      • Our Team
      • Our Partners
      • Our Business Model
    • Our Science
      • History
      • Unique 3D Approach
      • Patented Technology
      • Scientific Publications
    • Our products
      • 3D Alzheimer's & TAUpathy
      • 3D Brain Development
      • 3D Toxicity
      • 3D Glioblastoma ex vivo
      • 3D Customizable Products
    • Our facilities
    • Proprietary Rights
    • News
  • Main
  • About us
    • Our Team
    • Our Partners
    • Our Business Model
  • Our Science
    • History
    • Unique 3D Approach
    • Patented Technology
    • Scientific Publications
  • Our products
    • 3D Alzheimer's & TAUpathy
    • 3D Brain Development
    • 3D Toxicity
    • 3D Glioblastoma ex vivo
    • 3D Customizable Products
  • Our facilities
  • Proprietary Rights
  • News

Patented Technology

  

Our hydrogel technology and its scientific tenets belong solely to Neuron-D GmbH under the license auspices of Leibniz Institute for Polymer Research Dresden e.V. (IPF) and the German Center for Neurodegenerative Diseases (DZNE). Our innovative technology is based on many impactful scientific publications in world-leading journals. 


Neuron-D GmbH was founded in Dresden as a spin-off of the IPF and the DZNE and is currently conducting its business activities at the company's headquarters, the Bio-innovation Center Dresden (BiOZ). 


The method "Method for the formation of a functional network of human neuronal cells" has been applied for protection in Germany DE 102016 109 068.9 and internationally PCT WO2017198258A1 (nationalization in DE, EP, US, CA, IN, JP, AUS, BR, KR, CHN). The IPR application is jointly held by IPF and DZNE and Neuron-D GmbH has been granted an exclusive, worldwide license to the IPR by the patent holders (IPF and DZNE). In addition, there is an intellectual property right granted in US, JP, DE, GB, FRA, ITA, ESP, NL, and CH (priority year 2008, Bioactive Hydrogel, WO2010060485A1) which protects the hydrogel material on which the process is based. This patent belongs to ZetaSCIENCE GmbH (spin-off from IPF and SME based in Dresden). ZetaSCIENCE GmbH granted Neuron-D GmbH an exclusive license of the patent family for all neuron-related applications in the hydrogel materials and is a strategic supplier of hydrogel materials for Neuron-D GmbH. 


Copyright © 2022  All Rights Reserved Neuron D GmbH

  • Privacy policy
  • Impressum
  • Contact Us

Powered by Website Builder

3D Glioblastoma ex vivo

We are excited to launch our 3D model of human Glioblastoma multiforme, one of the most aggressive tumors of our brains. 

Learn more

Cookie Policy

This website uses cookies. Cookie policies and information can be found under Privacy Policy. You can continue to the website after making your choice. 

DeclineAccept